The reported biomarkers to date have focused on evaluating the properties of cancer cells, including PD‐L1 expression levels,[6, 7, 8] tumor mutation burden (TMB),[9, 10] tumor‐infiltrating lymphocyte (TIL) counts,[11] and neoantigen load.[12, 13] No biomarkers have been systematically used to evaluate tumor‐specific immune responses in tumor‐bearing bodies. This evidence concerns the gene CD274 and neoplasm.